Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | USP2 | O75604 | 7/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CASP1 | P29466 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285671 | 0.90 | MEN1 (0.53) | KMT2AALDH1A1MEN1JAK2PTK2 | |
| SCHEMBL16285681 | 0.87 | FYN (0.56) | JAK2EGFRJAK1TYK2JAK3 | |
| SCHEMBL16285670 | 0.87 | NTRK1 (0.50) | KMT2AJAK2EGFRJAK1TYK2 | |
| SCHEMBL16285675 | 0.87 | EGFR (0.49) | JAK2PTK2EGFRJAK1TYK2 | |
| SCHEMBL10192665 | 0.83 | JAK3 (0.70) | KMT2AUSP2CYP3A4ALDH1A1MEN1 | |
| SCHEMBL16285698 | 0.82 | CDK4 (0.48) | JAK2EGFRJAK1TYK2JAK3 | |
| SCHEMBL16285673 | 0.82 | FYN (0.56) | JAK2PTK2EGFRJAK1TYK2 | |
| SCHEMBL16285677 | 0.82 | JAK2 (0.49) | KMT2AALDH1A1JAK2PTK2JAK3 | |
| SCHEMBL16285697 | 0.82 | MAPT (0.51) | CYP3A4ALDH1A1CYP1A2HSD17B10JAK2 | |
| SCHEMBL16285674 | 0.82 | CDK4 (0.50) | JAK2EGFRJAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | KMT2A 1745/4885USP2 618/4885CYP3A4 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.